Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer.

IF 2.2 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Tomography Pub Date : 2024-10-07 DOI:10.3390/tomography10100117

Yusuke Kurita, Daisuke Utsunomiya, Kensuke Kubota, Shingo Koyama, Sho Hasegawa, Kunihiro Hosono, Kuniyasu Irie, Yuichi Suzuki, Shin Maeda, Noritoshi Kobayashi, Yasushi Ichikawa, Itaru Endo, Atsushi Nakajima

{"title":"Diagnostic Value of Contrast-Enhanced Dual-Energy Computed Tomography in the Pancreatic Parenchymal and Delayed Phases for Pancreatic Cancer.","authors":"Yusuke Kurita, Daisuke Utsunomiya, Kensuke Kubota, Shingo Koyama, Sho Hasegawa, Kunihiro Hosono, Kuniyasu Irie, Yuichi Suzuki, Shin Maeda, Noritoshi Kobayashi, Yasushi Ichikawa, Itaru Endo, Atsushi Nakajima","doi":"10.3390/tomography10100117","DOIUrl":null,"url":null,"abstract":"Background/Objectives: The usefulness of dual-energy computed tomography (DECT) for low absorption in the parenchymal phase and contrast effects in the delayed phase for pancreatic cancer is not clear. Therefore, the diagnostic capability of low-KeV images obtained using DECT for pancreatic cancer in the pancreatic parenchymal and delayed phases was evaluated quantitatively and qualitatively. Methods: Twenty-five patients with pancreatic cancer who underwent contrast-enhanced DECT were included. A total of 50 and 70 KeV CT images, classified as low-keV and conventional CT-equivalent images, were produced, respectively. The tumor-to-pancreas contrast (Hounsfield units [HU]) in the pancreatic parenchymal and delayed phases was calculated by subtracting the CT value of the pancreatic tumor from that of normal parenchyma. Results: The median tumor-to-pancreas contrast on 50 KeV CT in the pancreatic parenchymal phase (133 HU) was higher than that on conventional CT (68 HU) (p < 0.001). The median tumor-to-pancreas contrast in the delayed phase was -28 HU for 50 KeV CT and -9 HU for conventional CT (p = 0.545). For tumors < 20 mm, the tumor-to-pancreas contrast of 50 KeV CT (-39 HU) had a significantly clearer contrast effect than that of conventional CT (-16.5 HU), even in the delayed phase (p = 0.034). Conclusions: These 50 KeV CT images may clarify the low-absorption areas of pancreatic cancer in the pancreatic parenchymal phase. A good contrast effect was observed in small pancreatic cancers on 50 KeV delayed-phase images, suggesting that DECT is useful for the visualization of early pancreatic cancer with a small tumor diameter.","PeriodicalId":51330,"journal":{"name":"Tomography","volume":"10 10","pages":"1591-1604"},"PeriodicalIF":2.2000,"publicationDate":"2024-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510840/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Tomography","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/tomography10100117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Background/Objectives: The usefulness of dual-energy computed tomography (DECT) for low absorption in the parenchymal phase and contrast effects in the delayed phase for pancreatic cancer is not clear. Therefore, the diagnostic capability of low-KeV images obtained using DECT for pancreatic cancer in the pancreatic parenchymal and delayed phases was evaluated quantitatively and qualitatively. Methods: Twenty-five patients with pancreatic cancer who underwent contrast-enhanced DECT were included. A total of 50 and 70 KeV CT images, classified as low-keV and conventional CT-equivalent images, were produced, respectively. The tumor-to-pancreas contrast (Hounsfield units [HU]) in the pancreatic parenchymal and delayed phases was calculated by subtracting the CT value of the pancreatic tumor from that of normal parenchyma. Results: The median tumor-to-pancreas contrast on 50 KeV CT in the pancreatic parenchymal phase (133 HU) was higher than that on conventional CT (68 HU) (p < 0.001). The median tumor-to-pancreas contrast in the delayed phase was -28 HU for 50 KeV CT and -9 HU for conventional CT (p = 0.545). For tumors < 20 mm, the tumor-to-pancreas contrast of 50 KeV CT (-39 HU) had a significantly clearer contrast effect than that of conventional CT (-16.5 HU), even in the delayed phase (p = 0.034). Conclusions: These 50 KeV CT images may clarify the low-absorption areas of pancreatic cancer in the pancreatic parenchymal phase. A good contrast effect was observed in small pancreatic cancers on 50 KeV delayed-phase images, suggesting that DECT is useful for the visualization of early pancreatic cancer with a small tumor diameter.

查看原文本刊更多论文

对比增强型双能量计算机断层扫描对胰腺实质期和延迟期胰腺癌的诊断价值

背景/目的：双能计算机断层扫描（DECT）在胰腺实质期的低吸收和延迟期的对比效应对胰腺癌的作用尚不明确。因此，对使用 DECT 获得的胰腺实质期和延迟期胰腺癌低 KeV 图像的诊断能力进行了定量和定性评估。方法：纳入了 25 名接受造影剂增强 DECT 的胰腺癌患者。分别制作了 50 和 70 KeV CT 图像，分为低 KeV 和传统 CT 等效图像。将胰腺肿瘤的 CT 值减去正常实质的 CT 值，计算出胰腺实质期和延迟期的肿瘤与胰腺对比度（Hounsfield 单位 [HU]）。结果：胰腺实质期 50 KeV CT 的肿瘤与胰腺对比度中值（133 HU）高于常规 CT 的肿瘤与胰腺对比度中值（68 HU）（P < 0.001）。在延迟期，50 KeV CT 的肿瘤与胰腺对比度中位数为 -28 HU，而传统 CT 为 -9 HU（p = 0.545）。对于小于 20 毫米的肿瘤，50 KeV CT 的肿瘤与胰腺对比度（-39 HU）明显比传统 CT 的对比度（-16.5 HU）更清晰，即使在延迟阶段也是如此（p = 0.034）。结论：这些 50 KeV CT 图像可清晰显示胰腺实质期胰腺癌的低吸收区。在 50 KeV 延迟相图像上观察到小胰腺癌有良好的对比效果，这表明 DECT 可用于观察肿瘤直径较小的早期胰腺癌。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Tomography Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

2.70

自引率

10.50%

发文量

222

期刊介绍： TomographyTM publishes basic (technical and pre-clinical) and clinical scientific articles which involve the advancement of imaging technologies. Tomography encompasses studies that use single or multiple imaging modalities including for example CT, US, PET, SPECT, MR and hyperpolarization technologies, as well as optical modalities (i.e. bioluminescence, photoacoustic, endomicroscopy, fiber optic imaging and optical computed tomography) in basic sciences, engineering, preclinical and clinical medicine. Tomography also welcomes studies involving exploration and refinement of contrast mechanisms and image-derived metrics within and across modalities toward the development of novel imaging probes for image-based feedback and intervention. The use of imaging in biology and medicine provides unparalleled opportunities to noninvasively interrogate tissues to obtain real-time dynamic and quantitative information required for diagnosis and response to interventions and to follow evolving pathological conditions. As multi-modal studies and the complexities of imaging technologies themselves are ever increasing to provide advanced information to scientists and clinicians. Tomography provides a unique publication venue allowing investigators the opportunity to more precisely communicate integrated findings related to the diverse and heterogeneous features associated with underlying anatomical, physiological, functional, metabolic and molecular genetic activities of normal and diseased tissue. Thus Tomography publishes peer-reviewed articles which involve the broad use of imaging of any tissue and disease type including both preclinical and clinical investigations. In addition, hardware/software along with chemical and molecular probe advances are welcome as they are deemed to significantly contribute towards the long-term goal of improving the overall impact of imaging on scientific and clinical discovery.